About
Acalabrutinib is a highly selective, potent, and irreversible second-generation Bruton's tyrosine kinase (BTK) inhibitor. It functions by covalently binding to a cysteine residue in the active site of BTK, an enzyme that plays a critical role in the B-cell receptor signaling pathway, which is essential for B-cell development, differentiation, and survival. In various B-cell malignancies, this pathway is often hyperactive, contributing to uncontrolled cell proliferation. By inhibiting BTK, acalabrutinib disrupts these aberrant signaling cascades, leading to reduced proliferation and increased apoptosis of malignant B-cells. Its design aims to minimize off-target inhibition of other kinases, potentially resulting in a more favorable safety profile, particularly regarding cardiovascular adverse events, compared to earlier BTK inhibitors. This makes acalabrutinib a valuable and often preferred treatment option for specific hematologic cancers such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL).
Uses
- Mantle cell lymphoma (MCL) in adults who have received at least one prior therapy
- Chronic lymphocytic leukemia (CLL)
- Small lymphocytic lymphoma (SLL)
- Waldenström's macroglobulinemia (WM)
- Other B-cell lymphomas
Directions For Use
Take orally twice daily, with or without food, at approximately the same time each day, or as directed by your physician.
Benefits
- High response rates in B-cell malignancies
- Improved progression-free survival
- Oral administration
- Targeted therapy with fewer off-target effects
- Effective in relapsed/refractory cases
- Generally well-tolerated
Side Effects
- Headache
- Diarrhea
- Fatigue
- Muscle pain
- Bruising
- Nausea
- Anemia
- Neutropenia
- Thrombocytopenia
- Atrial fibrillation
- Hemorrhage
- Infections
Safety Measures
- Alcohol - Avoid or limit alcohol consumption, as it may increase the risk of bleeding or gastrointestinal side effects.
- Pregnancy - Not recommended during pregnancy due to potential for fetal harm. Women of childbearing potential should use effective contraception.
- Breastfeeding - It is unknown if Acalabrutinib is excreted in human milk. Breastfeeding is not recommended due to potential for serious adverse reactions in the infant.
- Liver - Use with caution in patients with hepatic impairment; dose adjustments may be necessary, and liver function should be monitored.
- Kidney - No specific dose adjustment is required for mild to moderate renal impairment, but caution is advised in severe cases.
- Lung - Rare cases of pneumonitis have been reported; monitor for new or worsening respiratory symptoms.
Disclaimer
MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.
Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.
Our goal is to complement, not replace, the essential doctor-patient relationship.
| Shipping Cost |
|
| Shop Location | Assam, India |
No comments found for this product. Be the first to comment!